We are live on ! Find out more
PEAR

Pear Therapeutics, Inc. Class A Common Stock
PEAR

Delisted

PEAR was delisted on the 18th of April, 2023.

Back to rankings

72 hedge funds and large institutions have $203M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,400% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 1

654% more capital invested

Capital invested by funds: $26.9M → $203M (+$176M)

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

300% more funds holding

Funds holding: 18 → 72 (+54)

Holders
72
Holders Change
+54
Holders Change %
+300%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
55
Increased
7
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CM
Cohanzick Management
New York
+$13.8M
2
RA
RiverPark Advisors
New York
+$12.8M
3
AC
Aristeia Capital
Connecticut
+$11.8M
4
Nomura Holdings
Nomura Holdings
Japan
+$11.5M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.81M

Top Sellers

Rank Fund Capital Flow
1
OCM
Oribel Capital Management
New York
-$13.4K
2
BCM
Basso Capital Management
Connecticut
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$17M +$9.81M +1,000,021 +140%
CM
2
Cohanzick Management
New York
$13.9M +$13.8M +1,405,348 New
RA
3
RiverPark Advisors
New York
$12.9M +$12.8M +1,304,598 New
AC
4
Aristeia Capital
Connecticut
$11.9M +$11.8M +1,200,000 New
Nomura Holdings
5
Nomura Holdings
Japan
$11.6M +$11.5M +1,175,598 New
GCL
6
Glazer Capital LLC
New York
$7.35M +$7.3M +744,195 New
Millennium Management
7
Millennium Management
New York
$7.16M +$7.11M +725,129 New
PC
8
Periscope Capital
Ontario, Canada
$6.9M +$6.85M +698,700 New
SCM
9
Saba Capital Management
New York
$6.85M +$273K +27,865 +4%
SC
10
Sculptor Capital
New York
$6.51M +$4.5M +459,268 +230%
Marshall Wace
11
Marshall Wace
United Kingdom
$5.44M +$5.4M +550,188 New
RCM
12
Radcliffe Capital Management
Pennsylvania
$5.44M +$5.4M +550,397 New
KC
13
Kepos Capital
New York
$5.19M +$5.15M +525,000 New
MCM
14
Moore Capital Management
New York
$4.95M +$4.9M +500,000 New
DKCM
15
Davidson Kempner Capital Management
New York
$4.94M +$4.9M +500,000 New
LA
16
Linden Advisors
New York
$4.9M +$4.86M +495,346 New
CCA
17
Castle Creek Arbitrage
Colorado
$3.46M +$3.43M +349,998 New
Verition Fund Management
18
Verition Fund Management
Connecticut
$3.45M +$1.64M +167,616 +93%
GCM
19
Ghisallo Capital Management
Massachusetts
$3.41M +$3.38M +345,000 New
Hudson Bay Capital Management
20
Hudson Bay Capital Management
Connecticut
$3.39M +$3.36M +342,630 New
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$3.2M +$3.18M +324,063 New
TCA
22
Taconic Capital Advisors
New York
$3.08M +$3.05M +310,899 New
KCM
23
Kingstown Capital Management
New York
$2.96M +$2.94M +300,000 New
TCM
24
Tenor Capital Management
New York
$2.96M +$2.94M +300,000 New
PSAMP
25
P. Schoenfeld Asset Management (PSAM)
New York
$2.96M +$2.94M +299,901 New
1
2 3

PEAR Hedge Fund Activity: Q2 2021 in Review

72 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q2 2021, worth a combined $203M — up 654% from $26.9M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new PEAR positions and 1 closed out — a net gain of 54 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Cohanzick Management, opening a new position worth an estimated $13.8M. The largest seller was Oribel Capital Management, cutting an estimated $13.4K.

  • 72 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q2 2021, up from 18 in Q1 2021.
  • Funds reported $203M of Pear Therapeutics, Inc. Class A Common Stock stock for Q2 2021, up 654% quarter-over-quarter.
  • 55 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q2 2021 and 1 closed out, a net change of +54 holders.
  • The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q2 2021 was Cohanzick Management, an estimated $13.8M added.
  • The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q2 2021 was Oribel Capital Management, an estimated $13.4K sold.

Based on aggregated 13F filings for Q2 2021.